Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
Cancer Medicine · 2024
DOI: 10.1002/cam4.70252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Wenjie Qin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, China. Hauptthemen laut MEDLINE: Cardiac Glycosides, Proteome, Molecular Docking Simulation, Solubility. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Cardiac glycosides (CGs), traditionally used for heart failure, have shown potential as anti‐cancer agents. This study aims to explore their multifaceted mechanisms in cancer cell biology using proteome integral solubility alteration (PISA), focusing on the interaction with key proteins implicated in cellular metabolism and mitochondrial function.
Methods
We conducted lysate‐based and intact‐cell PISA assays on cancer cells treated with CGs (Digoxin, Digitoxin, Ouabain) to analyze protein solubility changes. This was followed by mass spectrometric analysis and bioinformatics to identify differentially soluble proteins (DSPs). Molecular docking simulations were performed to predict protein‐CG interactions. Public data including gene expression changes upon CG treatment were re‐analyzed for validation.
Results
The PISA assays revealed CGs’ broad‐spectrum interactions, particularly affecting proteins like PKM2, ANXA2, SLC16A1, GOT2 and GLUD1. Molecular docking confirmed stable interactions between CGs and these DSPs. Re‐analysis of public data supported the impact of CGs on cancer metabolism and cell signaling pathways.
Conclusion
Our findings suggest that CGs could be repurposed for cancer therapy by modulating cellular processes. The PISA data provide insights into the polypharmacological effects of CGs, warranting further exploration of their mechanisms and clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, China.
- Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
- Institute of Clinical Pharmacy, Central South University, Changsha, China.
- Shenzhen Wininnovate Bio-Tech Co., Ltd, Shenzhen, China.
ORCID-Profile: Zhiling Yang
Zitieren
APA
Qin, W., Deng, Y., Ren, H., Liu, Y., Liu, L., Liu, W., Zhao, Y., Li, C., & Yang, Z. (2024). Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach. Cancer Medicine. https://doi.org/10.1002/cam4.70252
Vancouver
Qin W, Deng Y, Ren H, Liu Y, Liu L, Liu W, et al. Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach. Cancer Medicine. 2024. doi:10.1002/cam4.70252
BibTeX
@article{Qin2024,
author = {Qin, Wenjie and Deng, Yinhua and Ren, Huan and Liu, Yanling and Liu, Ling and Liu, Wenhui and Zhao, Yuxi and Li, Chen and Yang, Zhiling},
title = {Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70252}
}
EUVIMED